Physiologic glucose transporters and metabolic enzymes

Physiologic glucose transporters and metabolic enzymes encompass a diverse group of proteins essential for maintaining glucose homeostasis and cellular energy production. This group includes the Solute Carrier Family 2 (GLUT) and Family 5 (SGLT) transporters, which facilitate glucose entry into cells and reabsorption in the kidneys (StatPearls, NBK537223). Key metabolic enzymes such as hexokinase, phosphofructokinase, and pyruvate kinase govern the glycolytic pathway, while glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK) regulate gluconeogenesis (NCBI, NBK22501). Dysregulation of these proteins is central to the pathogenesis of Type 2 Diabetes Mellitus and metabolic syndrome, leading to the development of drugs like SGLT2 inhibitors (e.g., Empagliflozin) and biguanides (Metformin) (PubMed, 29070544). Furthermore, the "Warburg effect" in oncology highlights the overexpression of these transporters and enzymes in malignant cells to support high glycolytic flux, making them potential targets for anti-cancer therapies (PubMed, 24561201). Pharmacological modulation of these pathways can involve direct inhibition of transport or allosteric regulation of enzymatic activity to restore metabolic balance or selectively starve diseased cells.

Other names

Glucose transport systemGlycolytic enzymesGluconeogenic enzymesSLC2 familySLC5 familyGlucose handling proteins

Drugs targeting this group act by inhibiting glucose reabsorption in the proximal tubule (SGLT2 inhibitors), promoting the translocation of glucose transporters to the cell membrane (Insulin), or inhibiting key rate-limiting enzymes in glycolysis or gluconeogenesis to modulate metabolic flux (PubMed, 30124461).